Navigating HIV Care with GLP-1 Receptor Agonists – Dr Darcy Wooten
In episode 55 of Going anti-Viral, Dr Darcy Wooten joins host Dr Michael Saag to discuss navigating HIV care with glucagon-like peptide-1 (GLP-1) receptor agonists. Dr Wooten is a Professor of Medicine in the Division of Infectious Diseases at Washington University in St. Louis. Her clinical interests are HIV primary care, HIV prevention, sexually transmitted infections, and general infectious diseases. Dr Wooten is also a national leader in medical education. Dr Wooten provides an overview of GLP-1 receptor agonists including their history of use for the treatment of diabetes and more recent use for treatment of weight loss. Dr Saag and Dr Wooten discuss the challenges that patients have in getting insurance coverage for GLP-1 receptor agonists and review the 2 most common drugs that are used as treatment, tirzepatide and semaglutide. They discuss the patient experience with the injectable medication and review the possibility of oral versions of the medications in the future. Finally, Dr Saag and Dr Wooten discuss the long-term management of GLP-1 receptor agonists as a part of overall primary care for patients with HIV. 0:00 – Introduction 1:11 – Overview of GLP-1 receptor agonists 3:46 – How GLP-1 receptor agonists became used for weight management and patient eligibility criteria 6:14 – Challenges of insurance coverage for GLP-1 receptor agonists 8:32 – Differences between the GLP-1 receptor agonists tirzepatide and semaglutide and other benefits of the medications beyond weight loss 12:04 – Patient experience with the injectable formulations and possible adverse effects of use 14:36 – Long-term use of GLP-1 receptor agonists and possibility of oral versions of these drugs 17:36 – Managing GLP-1 receptor agonists as a part of primary care for patients with HIV including treatment of some substance use disorders 20:22 – Predictions for future management of GLP-1 receptor agonists and Dr Wooten’s hope for more research into incorporating lifestyle modifications into patient care

GLP-1 Receptor Agonists in People With HIV: Emerging Evidence and Clinical Implications

Challenging Cases in Advanced HIV: Managing Opportunistic Infections and New Guidance on ART

Microdosing GLP-1: A New Approach to Inflammation-Driven Diseases | Empowering Midlife Wellness

Updates from CROI 2026

I’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.

Doctor reveals undisclosed risks of COVID-19 vaccine

THESE Apps Are SPYING on You — Shut Them Off NOW!

How I Found Out I was HIV+

Colin Farrell Opens Up About His Son With Angelman Syndrome | PEOPLE

Dr. Explains Why Retatrutide is KING of Fat Loss Peptides

Serial Killers Seem To Be Disappearing. Here's Why | Criminal Psychology

Ozempic vs. Mounjaro | Which one actually protects you?

The Impact of Long-acting Injectable HIV Treatments on Public Health – Dr Kelly Gebo

Doku: Die geheime Welt des deutschen Adels

Did I Get HIV!? What Are The Symptoms?

Going anti-Viral: Episode 4 - A Deep Dive Into Vaccine Development With Dr Richard Koup.

Cases in HIV Medicine: Putting it all Together

DeLIVERing Prevention Podcast: Optimizing Uptake of Hepatitis A and B Vaccination

What Happens To Your Dopamine Week By Week When You Stop Drinking?

